Assetmark Inc. Invests $563,000 in Dyne Therapeutics, Inc. $DYN

Assetmark Inc. acquired a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 31,062 shares of the company’s stock, valued at approximately $563,000.

Several other institutional investors have also added to or reduced their stakes in DYN. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the 1st quarter valued at approximately $26,000. Strs Ohio bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $84,000. Steward Partners Investment Advisory LLC boosted its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. 96.68% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Jason P. Rhodes sold 480,240 shares of Dyne Therapeutics stock in a transaction on Monday, July 6th. The shares were sold at an average price of $22.79, for a total value of $10,944,669.60. Following the completion of the sale, the director owned 875,912 shares of the company’s stock, valued at approximately $19,962,034.48. This trade represents a 35.41% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,892,879 shares valued at $40,500,030. 9.46% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. TD Cowen assumed coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a “buy” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research report on Friday, May 15th. Finally, Sanford C. Bernstein boosted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.17.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $24.44 on Monday. The business’s 50 day simple moving average is $20.38 and its two-hundred day simple moving average is $18.62. The firm has a market cap of $4.56 billion, a P/E ratio of -7.59 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a quick ratio of 19.92 and a current ratio of 19.92. Dyne Therapeutics, Inc. has a 52-week low of $8.88 and a 52-week high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.77) by $0.04. During the same period in the prior year, the company posted ($1.05) EPS. As a group, research analysts forecast that Dyne Therapeutics, Inc. will post -3.01 EPS for the current fiscal year.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.